Private company

Immedica Pharma AB

Immedica Pharma AB is a limited company registered in Sweden, based in Stockholm, active since 2010.¹

Last updated Oct 21, 2026.

Overview

Dec 23, 2010Founded¹

HeadquartersStockholm, Sweden¹
Legal formAktiebolag¹
LEI549300Q0QKHL3MF7FV02¹
StatusActive¹
LEI statusIssued and current¹
Registered addressSolnavägen 3H, 113 63 Stockholm, Sweden¹
Registered withSwedish Companies Registration Office, 556835-6322¹

See how the biggest companies compare on our leaderboards

Corporate structure

Immedica Pharma AB is part of a group headed by Impilo Partners AB. 8 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Impilo Partners AB Stockholm, Sweden
- Immedica Pharma AB Stockholm, Sweden
- ULT Denmark ApS Vamdrup, Denmark
- Impilo Holding AB Subsidiary · Stockholm, Sweden
- Impilo Industrial Partners (No. 1) AB Subsidiary · Stockholm, Sweden
- Impilo Management (No. 1) AB Subsidiary · Stockholm, Sweden
- Impilo Management (No. 2) AB Subsidiary · Stockholm, Sweden
- Impilo Management (No.3) AB Subsidiary · Stockholm, Sweden

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0). Each entity in the chart links to its source.

Subsidiaries and ownership

Ultimate parent

Impilo Partners AB¹

Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.

Timeline

Dec 23, 2010Founded Immedica Pharma AB is founded¹

Calendar

Drug trials and FDA: recently

Feb 23, 2026FDA approval FDA approved Loargys (pegzilarginase-nbln), a new molecular entity, priority review, orphan drug (BLA 761211).²
Jan 15, 2026Phase 3 trial completed Phase 3 trial of Chronocort in Congenital Adrenal Hyperplasia: primary completion Jan 15, 2026, no results posted yet (ClinicalTrials.gov NCT05299554).³
Oct 16, 2025FDA approved a new use FDA approved an efficacy supplement for Ztalmy (ganaxolone), a new use or patient group (NDA 215904, supplement 11).⁴
Jun 17, 2025Phase 3 trial completed Phase 3 trial of Pegzilarginase in Arginase 1 Deficiency: primary completion Jun 17, 2025, results posted Apr 30, 2026 (ClinicalTrials.gov NCT06582524).⁵
Dec 15, 2022Phase 2 trial completed Phase 2 trial of AEB1102 in Arginase I Deficiency: primary completion Dec 15, 2022, results posted Sep 24, 2026 (ClinicalTrials.gov NCT03378531).⁶

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.